Atea Pharmaceuticals, Inc. AVIR
We are a late-stage clinical biopharmaceutical company leveraging our deep understanding of antiviral drug development, medicinal chemistry, biochemistry and virology to discover, develop and commercialize novel, orally administered antivirals to treat serious viral diseases. Our current product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which we believe has the potential to improve the current standard of care ("SOC") for the treatment of patients with hepatitis C virus ("HCV") infection and AT-587 which we believe has the potential to be the first direct-acting antiviral ("DAA") for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus ("HEV") infection.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $351.4M | $48.6M | — | — | — |
| R&D | $148.0M | $144.1M | $114.2M | $81.9M | $167.2M | $38.0M | $10.2M | $6.7M | — |
| SG&A | $32.9M | $48.8M | $49.9M | $48.7M | $45.8M | $21.6M | $4.4M | $2.8M | — |
| Total operating expenses | $180.9M | $192.9M | $164.2M | $130.7M | $213.0M | $59.7M | $14.6M | $9.5M | — |
| Operating income | -$180.9M | -$192.9M | -$164.2M | -$130.7M | $138.4M | -$11.0M | -$14.6M | -$9.5M | — |
| Pre-tax income | -$164.5M | -$167.5M | -$134.9M | -$119.5M | $138.6M | -$10.9M | -$14.0M | — | — |
| Income tax | $6.2M | $925.0K | $1.0M | $3.6M | $17.4M | — | — | — | — |
| Net income | -$158.0M | -$168.0M | -$136.0M | -$116.0M | $121.0M | -$10.9M | -$14.0M | -$9.1M | — |
| EPS, basic | -1.94 | -2.00 | -1.63 | -1.39 | 1.46 | -0.51 | -1.39 | — | — |
| EPS, diluted | -1.94 | -2.00 | -1.63 | -1.39 | 1.37 | -0.51 | -1.39 | -0.90 | — |
| Shares, diluted (wtd. avg.) | $81.5M | $84.3M | $83.4M | $83.2M | $88.2M | $21.6M | $10.1M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $95.7M | $64.7M | $143.8M | $188.7M | $764.7M | $850.1M | $21.8M | $34.6M | $15.0M |
| Short-term investments | $206.1M | $390.0M | $434.3M | $458.2M | — | — | — | — | — |
| Total current assets | $311.0M | $462.4M | $590.5M | $660.9M | $772.4M | $863.5M | $21.9M | — | — |
| Property, plant and equipment | $457.0K | $873.0K | $1.3M | $1.7M | $23.0K | $48.0K | $41.0K | — | — |
| Total assets | $315.2M | $464.7M | $595.0M | $666.7M | $772.9M | $863.6M | $22.1M | — | — |
| Accounts payable | $12.9M | $4.5M | $4.3M | $2.6M | $4.5M | $60.0K | $548.0K | — | — |
| Total current liabilities | $39.8M | $18.6M | $32.4M | $18.5M | $56.9M | $315.8M | $2.4M | — | — |
| Total liabilities | $39.8M | $25.8M | $39.8M | $26.1M | $62.8M | $315.8M | $2.5M | — | — |
| Retained earnings | -$522.6M | -$364.2M | -$195.8M | -$59.9M | $56.0M | -$65.2M | -$54.2M | — | — |
| Total equity | $275.4M | $438.9M | $555.2M | $640.6M | $710.1M | $547.8M | -$49.6M | -$36.2M | -$27.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$132.0M | -$135.5M | -$85.4M | -$121.0M | -$87.0M | $296.7M | -$12.8M | -$7.9M | — |
| Stock-based compensation | $20.7M | $51.8M | $49.4M | $46.7M | $39.6M | $7.5M | $624.0K | $414.0K | — |
| Capital expenditure | — | — | — | $1.9M | $4.0K | $26.0K | $2.0K | $12.0K | — |
| Investing cash flow | $188.8M | $56.1M | $40.3M | -$455.4M | -$4.0K | -$26.0K | -$2.0K | -$12.0K | — |
| Financing cash flow | -$25.7M | $267.0K | $257.0K | $370.0K | $1.5M | $531.7M | — | $27.5M | — |
| Buybacks | $25.5M | $0 | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-182293.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |